Cardiac Disease in HIV-1 Tg Animals

2004 ◽  
pp. 408-418 ◽  
Keyword(s):  
1996 ◽  
Vol 6 (2) ◽  
pp. 143-148
Author(s):  
Luciano De Simone ◽  
Maurizio de Martino ◽  
Luisa Galli ◽  
Adriano Manetti ◽  
Silvia Favilli ◽  
...  

AbstractSince 1985 a physical and instrumental cardiac study was carried out in 41 children with perinatal HIV-1 infection in order to assess the prevalence and natural history of cardiac involvement. Children were followed for 66 (range 8-109) months; eight of 41 died of HIV-1 related diseases. The cumulative proportion of children with cardiac manifestations at age of seven years was 14.9% (95% CI: 4.9-31.5%). Cardiac abnormalities were detected in eight of 41 patients (19.5%) and were more significantly (p=0.003) recorded in children who died of HIV-1 related diseases (five of eight, 62.5%). Left ventricular systolic function was normal in most patients during the follow-up and did not depend on zidovudine treatment. Two patients had a severe dilated cardiomyopathy and underwent subsequently a stable regression as far as the clinical and instrumental frame was concerned. Only one patient died because of cardiac disease. We conclude that in our group ofperinatally HIV- 1 infected children, cardiac involvement is relatively rare, represents a late complication compared to other related HIV-1 diseases and occurs in advanced stages of illness. Cardiac disease is therefore a hallmark of poor prognosis, but is rarely the ultimate cause of death.


Author(s):  
James K. Koehler ◽  
Steven G. Reed ◽  
Joao S. Silva

As part of a larger study involving the co-infection of human monocyte cultures with HIV and protozoan parasites, electron microscopic observations were made on the course of HIV replication and infection in these cells. Although several ultrastructural studies of the cytopathology associated with HIV infection have appeared, few studies have shown the details of virus production in “normal,” human monocytes/macrophages, one of the natural targets of the virus, and suspected of being a locus of quiescent virus during its long latent period. In this report, we detail some of the interactions of developing virons with the membranes and organelles of the monocyte host.Peripheral blood monocytes were prepared from buffy coats (Portland Red Cross) by Percoll gradient centrifugation, followed by adherence to cover slips. 90-95% pure monocytes were cultured in RPMI with 5% non-activated human AB serum for four days and infected with 100 TCID50/ml of HIV-1 for four hours, washed and incubated in fresh medium for 14 days.


1997 ◽  
Vol 23 (3) ◽  
pp. 83-92 ◽  
Author(s):  
D. Seilhean ◽  
A. Dzia-Lepfoundzou ◽  
V. Sazdovitch ◽  
B. Cannella ◽  
C. S. Raine ◽  
...  

2000 ◽  
Vol 14 (2) ◽  
pp. 50-55
Author(s):  
FORTHEPEDIATRICPULMONARYANDCA ◽  
H COHEN ◽  
X CHEN ◽  
S SUNKLE ◽  
L DAVIS ◽  
...  

2020 ◽  
Author(s):  
Juan Ambrosioni ◽  
Elisa Petit ◽  
Geoffroy Liegeon ◽  
Montserrat Laguno ◽  
José M Miró
Keyword(s):  

2014 ◽  
Vol 71 (8) ◽  
pp. 451-460
Author(s):  
Jörg Schüpbach ◽  
Christoph Berger ◽  
Jürg Böni ◽  
Roberto F. Speck
Keyword(s):  
Hiv Test ◽  

„HIV-positiv“ ist auch heute noch eine belastende Diagnose. Falsch positive wie falsch negative HIV-Test-Resultate herauszugeben, muss unbedingt vermieden werden. Das Bundesamt für Gesundheit (BAG) hat ein HIV-Testkonzept entworfen, das dieser Anforderung gerecht wird und darüber hinaus das Virus im betroffenen Patienten detailliert für eine optimale medizinische Betreuung charakterisiert. Das Testkonzept fordert hierzu die Beantwortung der folgenden vier Fragen: 1. Ist die getestete Person tatsächlich HIV-infiziert? 2. Handelt es sich um eine Infektion mit HIV-1 oder HIV-2, und im Falle von HIV-1, um welche Virusgruppe, M oder O? Sind Resistenzen gegenüber den antiretroviralen Medikamenten vorhanden? 3. Wie hoch ist die Viruslast? 4. Wie hoch ist der Anteil frischer HIV-Infektionen an den neu gemeldeten Fällen? In diesem Artikel werden wir das Testkonzept besprechen. Abschliessend werden wir in einer kurzen Übersicht darlegen, was der Arzt bei einer Erst- und Folgekonsultation bei einem HIV-infizierten Patienten abklären sollte.


Sign in / Sign up

Export Citation Format

Share Document